Key Insights

Highlights

Treatment Research

6 treatments under study, led by Ethambutol

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 2 (1)

Trial Status

Not Yet Recruiting1

Clinical Trials (1)

Showing 1 of 1 trials
NCT06917495Phase 2Not Yet RecruitingPrimary

Short-Course Anti-tuberculosis Regimens for Mild Spinal Tuberculosis

Showing all 1 trials

Research Network

Common Treatments

  • Ethambutol1
  • Moxifloxacin1
  • Isoniazid1
  • Pyrazinamide1
  • Rifampin1

Active Sponsors

  • Shandong Public Health Clinical Center1
  • Shandong University1

Top Investigators

Activity Timeline